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Objective. To determine the origin, distribution, 
and biologic fate of platelet-derived connective tissue 
activating peptid+III (CTAP-111), to define the relative 
amounts of the antigen forms (CTAP-111, beta- 
thromboglobulin [@-TG], neutrophil activating pep- 
tide-2 [NAP-21) in plasma of normal persons and those 
with rheumatic or end-stage renal disease, and to define 
the isoforms of CTAP-I11 in platelets, plasma, transu- 
dates, and tissue deposits. 
Methods. CTAP-111 in plasma was measured by 
enzyme-linked immunosorbent assay, and growth pro- 
moting activity of CTAP-III isoforms was tested in syno- 
vial and peritoneal cell cultures by measuring increased 
synthesis of ''C-glycosaminoglycan (14C-GAG) and 3H- 
DNA. Isolated CTAP-111 was characterized by Western 
blotting, microsequencing, and mass spectrometry. 
Results. CTAP-I11 was the primary isoform of 
this antigen family in normal platelets and platelet-rich 
plasma; @-TG and NAP-2 accounted for 4 %  of CTAP- 
I11 isoforms. Previously undescribed isoforms, i.e., 
CTAP-I11 des 1, des 1-2, des 1-3, and a phosphate 
adduct of CTAP-111, were observed in varying amounts. 
Elevated plasma levels of CTAP-I11 antigen were found 
in a substantial fraction of rheumatic disease patieats: 
24% of those with rheumatoid arthritis, 36% of those 
with systemic sclerosis, and 15% of those with systemic 
lupus erythematosus. All 10 patients with end-stage 
kidney disease had marked elevations of plasma CTAP- 
I11 levels, which stimulated DNA and GAG synthesis by 
peritoneal cells in culture. Only large isoforms (such as 
CTAP-111) were detected in venous plasma of normal 
subjects, rheumatic disease patients, and patients re- 
ceiving long-term dialysis. Normal human spleen and 
kidney contained substantial (pg/gm) amounts of 
CTAP-I11 and traces of an isoform with the electro- 
phoretic mobility of CTAP-I11 des 1-151NAP-2. Liver, 
lung, and urine contained lesser (ng/gm) amounts of 
Conclusion. These data show that, among the 10 
known isoforms, intact CTAP-111 itself was the major 
circulating isoform (>90%), and @-TG was the most 
rare (O-l%). Deposition of CTAP-I11 in tissues, such as 
synovium, spleen, and kidney, is associated with partial 
processing to NAP-%like isoforms and the potential to 
induce neutrophil and fibroblast activation in patients 
with rheumatic or end-stage renal disease. 
CTAP-111. 
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Connective tissue activating peptide-I11 
(CTAP-111) is a human platelet a-granule-derived 
growth factor that is more than 1,000 times as abun- 
dant as other growth factors in platelets. The amino 
acid sequence of CTAP-I11 has been determined and 
confirmed by cloning the gene (1-3). Early studies of a 
CTAP-I11 isoform, pthromboglobulin, (p-TG, identi- 
cal to CTAP-I11 des 1-4) did not attribute biologic 
activities to this entity. Radioimmunoassay (RIA) of 
p-TG indicated that it has a plasma half-time of 100 
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minutes and that it equilibrates with synovial and 
amniotic fluids but not cerebrospinal fluid; urine levels 
of P-TG antigen are -0.5% of venous plasma levels 
(4). Protein sequence homology studies show CTAP- 
I11 and its isoforms to be members of a family of 
proteins that includes neutrophil activating peptide-l 
(NAP-l)/interleukin-8, melanoma growth-stimulating 
activity, human GRO, 9E3, YIP-10, and platelet fac- 
tor-4, entities thought to be associated with growth, 
wound repair, inflammation, and neoplasia (5) .  Others 
have included these proinflammatory agonists in a 
supergene ‘‘intercrine” cytokine family (6). 
Many of the biologic activities of CTAP-I11 are 
anabolic; CTAP-I11 stimulates synthesis of DNA, hy- 
aluronic acid (HA), sulfated glycosaminoglycan 
(GAG) chains, proteoglycan monomer, and proteogly- 
can core protein in human synovial fibroblast cultures 
(1,7-10). CTAP-I11 also stimulates glucose transport, 
formation of prostaglandin E,, HA synthetase activity, 
and plasminogen activator activity (1 1-14). Elevated 
plasma levels of CTAP-III/PTG antigen have been 
found by RIA in patients with rheumatoid arthritis 
(RA), systemic sclerosis (SSc), systemic lupus erythe- 
matosus (SLE), and forms of vasculitis (15,16). Immu- 
noassay of CTAP-I11 in human serum shows concen- 
trations ranging from 5,000 to 35,000 nglml; such levels 
stimulate DNA and GAG synthesis in vitro and may 
resemble the amounts seen near connective tissue 
cells during blood clotting in microenvironments 
where platelet a-granule release occurs (17). 
Isoelectric focusing of CTAP-I11 from platelets 
stored frozen for years revealed marked structural 
microheterogeneity; subsequently, several amino- 
terminal cleavage products were found, which appear 
to result from proteolytic activity in platelet prepara- 
tions (17-19). Three isoforms, CTAP-I11 des 1-13, des 
1-14, and des 1-WNAP-2, stimulate I4C-GAG synthe- 
sis; the latter 2 isoforms also promote 3H-DNA syn- 
thesis in human fibroblast cultures (17,20). Recent data 
show that CTAP-I11 causes histamine release from 
basophil granules and that the CTAP-I11 (des 1-15)/ 
NAP-2 isoform is chemotactic for human neutrophils 
(21,22). A related study showed that CTAP-I11 and its 
isoforms compete with NAP-I for a receptor on human 
neutrophils (23). 
Both CTAP-I11 and an isoform with the electro- 
phoretic mobility of CTAP-III/NAP-2 have been de- 
tected in synovial tissue from patients with osteo- 
arthritis (OA) and RA (24). The finding of CTAP-I11 
isoforms in diseased tissue and data showing that some 
cleavage isoforms acquire new and potent biologic 
activities highlight the importance of studying qualita- 
tive and quantitative differences and distribution of 
CTAP-I11 isoforms in health and disease states. All 
CTAP-I11 isoforms (CTAP-111, CTAP-I11 des 1 -4 /p  
TG, CTAP-I11 des 1-13, CTAP-I11 des 1-14, and 
CTAP-111 des 1-15/NAP-2) are equally well detected 
by Western blotting using polyvalent antisera raised 
against CTAP-I11(17,18). The present study examined 
the quantity and isoforms of CTAP-I11 in platelets 
from circulating blood, plasma, urine, tissues, and 
organ storagelsequestration sites, thus providing a 
clearer idea of the relative amounts and distribution of 
specific CTAP-I11 isoforms. The investigations were 
performed using Western blotting and, where possible, 
microsequencing and/or mass spectrometry. 
PATIENTS AND METHODS 
Patient and control groups. All studies were carried 
out with protocols previously approved by the Institutional 
Review Board, with the informed consent of participating 
individuals. The normal control group comprised healthy 
volunteers from hospital personnel. 
Patients with diabetes, rheumatic disease, or renal 
disease. To clarify the relationship of CTAP-IIIIPTG anti- 
gen to diabetes, we studied patients with type I diabetes who 
were less than 40 years old. Patients were excluded if they 
had hypertension, vascular occlusive disease, diabetic ul- 
cers, renal insufficiency, or proliferative retinopathy, or if, in 
the prior week, they had taken a medication known to 
interfere with platelet function. 
Patients with rheumatic diseases met the American 
College of Rheumatology (formerly, the American Rheuma- 
tism Association) criteria for RA, SLE, or  SSc (25-27). A 
brief history, physical examination findings, and relevant 
laboratory data were recorded on a standardized form for 
each rheumatic disease patient, and a score thought to reflect 
the level of active inflammation was assigned based on the 
clinical data. Asymptomatic patients were given a score of 0, 
patients whose clinical symptoms had a minimal effect on 
functional status were given a score of 1, patients whose 
functional status was significantly impaired were given a 
score of 2, and those whose symptoms were so debilitating 
as to require maximal therapeutic intervention were given a 
score of 3. Virtually all patients were receiving antirheu- 
matic drugs at the time of blood sampling. 
Ten patients undergoing maintenance dialysis treat- 
ment for irreversible chronic renal failure were studied; 5 
were receiving hemodialysis and 5 were receiving long-term 
peritoneal dialysis. Samples from hemodialysis patients 
were obtained before dialysis, after 30 minutes of dialysis 
and at the end of the procedure. Blood samples from patients 
treated with peritoneal dialysis were obtained at random 
times during dialysis, and peritoneal dialysate fluid was 
collected after 3 hours of equilibration. 
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Patients undergoing coronary angioplasty . Fifteen 
patients were referred for elective coronary angioplasty for 
treatment of angina. The group included 13 men and 2 
women (mean -+ SD age 60 5 8 years); 10 had unstable 
angina pectoris. Coronary angioplasty was performed utiliz- 
ing standard techniques, including femoral artery cannula- 
tion with 8 or 9 French catheters to allow placement of 8 or 
9 French heparin-bonded coronary guiding catheters to 
instrument the coronary arteries. Patients received 325-975 
mg of aspirin for at least 2 days prior to the procedure; 
heparin (10,000 units) was infused as an intravenous bolus at 
the beginning of the procedure, and then 5,000 units was 
administered every 60 minutes thereafter. Several patients 
were receiving calcium channel blockers or nitrates. 
Collection and processing of blood samples for 
enzyme-linked immunosorbent assay (ELISA). Peripheral ve- 
nous blood was drawn from each subject's arm through a 
21-gauge butterfly needle. The initial 2-3 ml was discarded 
and the subsequent 3 ml was placed in a tube with 300 pl of 
a platelet-stabilizing solution (Thrombotect, consisting of 
2.5% EDTA, 0.025% 2-chloroadenosine, 7% procaine HCl), 
mixed by gentle inversion, and placed on ice. Plasma was 
separated from whole blood by centrifugation at 1,500g for 
30 minutes at 4°C and stored at -20°C. 
In the patients undergoing angioplasty, arterial and 
central venous blood samples for ELISA were obtained from 
the aorta, coronary arteries, inferior vena cava, and coro- 
nary sinus with a heparin-bonded balloon catheter, and 
anticoagulated as noted above. A 2.5-3.5-mm USCI LPS 2 
or Profile Plus balloon catheter was advanced to the tip of 
the guiding catheter to obtain the first sample for measure- 
ment of CTAP-111. Samples were obtained with slow aspira- 
tion into Thrombotect and heparin-containing syringes and 
placed on ice. The stenosis to be treated was then crossed 
with a 0.14 flexible, steerable guidewire which was used to 
support and direct the balloon catheter. The balloon catheter 
was centered on the stenosis and inflated to 4-10 atmo- 
spheres as many times as necessary (usually 2-6) to achieve 
an adequate posttreatment result. Following the final infla- 
tion, the guidewire was removed from the balloon catheter 
and another plasma sample was obtained. The balloon 
catheter was left across the stenosis and serial samples were 
obtained, usually at 5 ,  10, and 20 minutes after the final 
balloon inflation. The balloon catheter was then withdrawn 
proximal to the stenosis and further samples obtained. 
Measurement of CTAP-I11 in platelet-pack plasma. 
Platelet packs were obtained 1 day after the date of expira- 
tion for human use; after centrifugation at 1,375g for 20 
minutes at 4"C, supernatants were pooled and filtered 
through 0.65 pM and 0.22 p M  Millipore filters. CTAP-111 
was measured by radial immunodiffusion (RID); measure- 
ments of ring diameters were made at 48 hours and com- 
pared with known standards. Five observations were made 
on pools of 10 or more platelet units; 3 measurements were 
from individual bags containing 1, 4, or 6 units per bag. 
Isolation of CTAP-111 from human platelets, tissues, 
plasma, and other biologic fluids. CTAP-I11 was isolated from 
human platelets by acid-ethanol extraction, acetone precip- 
itation, gel filtration, heparin affinity chromatography, and 
immunoaffinity chromatography, as reported previously 
(18,28). Other tissue and fluid samples were also extracted 
with acid-ethanol and processed for Western blotting; in 
some instances, additional purification was carried out to 
facilitate structural studies. The extraction protocol utilized 
10 volumes of acid-ethanol (95% ethanol, 5% 1.25N HC1) 
per mi or gm of sample (plasma, platelet-pack plasma, 
peritoneal dialysis fluid, or tissue homogenates); after mix- 
ing, extraction was continued for 24-48 hours at 4°C with 
slow stirring. Preparations were centrifuged at 20,OOOg for 10 
minutes; the supernatant fluid was dialyzed against water, 
lyophilized, and reconstituted in a smaller volume for so- 
dium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). For structural studies, CTAP-111 was isolated 
from outdated platelet-pack plasma (-6 days post-blood 
donation) by acid-ethanol extraction, further simplified by 
agarose chromatography (CM Bio-Gel; Whatman, Hillsboro, 
OR), and subsequently isolated by immunoaffinity chroma- 
tography (24). Human spleen and other tissues were homog- 
enized as earlier reported for synovial tissue (24), extracted 
by acid-ethanol, and CTAP-I11 was then isolated (when 
CTAP-111 concentrations permitted) in the same manner as 
noted above for platelet-pack plasma. 
Protein measurement and antiserum development. 
Protein was measured by a colorimetric method (29) and/or 
UV absorption (30). Antiserum to native CTAP-111 and 
recombinant CTAP-111 (rCTAP-111) was raised in rabbits. 
Male New Zealand white rabbits (8-10 weeks old) were 
immunized with 500 pg of CTAP-111 in O.15M NaCl in 
Freund's complete adjuvant. Booster injections with anti- 
gens in Freund's incomplete adjuvant were given at 6 and 12 
weeks. Animals were bled at 4 weeks and then biweekly. 
Immunologic measurement of CTAP-111 isoforms. The 
ELISA used in these studies employs a double-antibody 
sandwich procedure using affinity-isolated anti-CTAP-I11 
antibody and its biotinylated counterpart with an avidin- 
biotin-peroxidase detection system (Vector Laboratories, 
Burlingame, CA) (28). Measurement of CTAP-I11 by RID 
utilized filtered, heat-inactivated rabbit anti-human CTAP- 
111 antiserum; this method is effective over a range of 2-50 
pdml (31). 
Analytic polyacrylamide gel electrophoresis. CTAP- 
I11 and its isoforms were analyzed by SDS-PAGE in 8M 
urea/8% total acrylamide (28,32). Proteins separated by 
SDS-PAGE were detected by either silver or Coomassie 
brilliant blue R-250 staining (28,33). Proteins separated by 
SDS-PAGE were prepared for Western blotting by transfer- 
ring onto Immobilon-P using a semi-dry blotter (Polyblot; 
American Bionetics, Hayward, CA) and then identified by 
Coomassie brilliant blue R-250 and immunostaining with 
antisera to rCTAP-I11 (28,32). Alternatively, Western blots 
of proteins, following electrophoretic separation, utilized 
immobilization in a nitrocellulose membrane (28). Mem- 
brane-bound antigens were probed with antisera to rCTAP- 
I11 (1500 or 1 :2,000) and the complexes were detected with 
a Bio-Rad immunoblot assay kit (horseradish peroxidase- 
conjugated goat anti-rabbit IgG; Bio-Rad, Richmond, CA) or 
by staining for alkaline phosphatase. 
Amino acid sequence determination. Aqueous protein 
solutions were applied to a glass fiber filter pretreated with 
2.0 mg of Biobrene and subjected to NH,-terminal sequenc- 
ing using an Applied Biosystems (Foster City, CA) 470A gas 
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phase protein sequencer interfaced with an Applied Biosys- 
tems 120A analyzer according to standard protocols (34). 
Mass spectrometric measurements. Mass measure- 
ments were made on a Vestec (Houston, TX) single quadru- 
ple mass spectrometer with a Vestec electrospray interface 
(35,36). The protein concentration utilized in these studies 
was 100 ng/ml in 4% acetic acid, 50% acetonitrile. The flow 
rate was 6 pl/minute. Data were acquired using a Teknivent 
Vector-2 acquisition system. The data were further pro- 
cessed, and the multiply charged ion series observed for 
each component were deconvoluted and the calculated val- 
ues determined using PROCOMP 1.2 (37). 
Cell culture methods. Cultures of human synovial 
cells from patients with OA were derived from explants 
obtained at arthrotomy (7,8). Monolayer cultures were 
grown in T-75 flasks in CMRL 1066 medium (Gibco, Grand 
Island, NY) supplemented with 5% human serum (HS), 10% 
neonatal calf serum (NCS), and 5% fetal calf serum (FCS), 
sodium bicarbonate, L-glutamine, 0.02M HEPES buffer, 
penicillin, streptomycin, and gentamicin. Cell strains were 
studied at the second through fifth passages after removal 
from explants. Cells from 500 ml of peritoneal dialysis fluid 
were pelleted by gentle centrifugation (- 1,000 revolutions 
per minute, in a model HN-S centrifuge; IEC, Needham 
Heights, MA) for 10 minutes. The cell pellet was resus- 
pended in 1.0 ml of peritoneal fluid and plated in a IO-mm 
well of a 24-well culture dish (Costar; Cambridge, MA). 
After 48 hours of incubation at 37°C in 95% air, 5% CO,, 
adherent cells were observed; the medium was then changed 
to CMRL 1066,, NCS,,HS,,FCS5 (supplemented as above) 
and incubation continued. After 9 days, there was confluent 
growth of fibroblast-like cells; these were passaged with 
trypsin to a 35-mm well of a 6-well culture dish for subse- 
quent study. 
Measurements of growth parameters by isotope incor- 
poration. Measurement of 14C-glucosamine incorporation 
into I4C-GAG, mostly I4C-HA, was effected by plating cells 
in 96-well microtiter plates, lo4 cells/well in 200 pl of 
semisynthetic medium (Leibovitz medium, L-15; Hazelton 
Biologics, Lenexa, KS), with 1% FCS, L-glutamine, peni- 
cillin, gentamicin, streptomycin, sodium carbonate, and 
0.02M HEPES buffer, pH 7.6 (7,28). Test materials and 
vehicles had contact with cells for -44 hours before medium 
was harvested for assay. Incorporation of isotope into se- 
creted I4C-HA was measured by scintillation counting fol- 
lowing the cetylpyridinium chloride-fixation wash proce- 
dure (7,28). 
To measure 3H-thymidine incorporation into syno- 
vial cell DNA, cells were plated, lo4 cells/microtiter well, in 
100 pl of Eagle's synthetic medium (ESM) supplemented 
with 1% FCS, antibiotics, L-glutamine, and HEPES buffer 
and incubated in a humidified chamber at 35-37°C (28,31). 
After 20 hours of incubation, test samples or vehicles were 
added (5-15 pUwe11) and incubation continued for 24 hours; 
3H-methylthymidine (1.5 pCi/lS pl ESM/well) was then 
added and incubation resumed for 24 hours. Medium was 
aspirated, discarded, and cell sheets were washed, first with 
phosphate buffered saline (pH 7.0), 5% trichloroacetic acid 
and then with absolute methanol. After drying at 35"C, cells 
were lysed for 1 hour at 37°C with 50 ml of 0.3N sodium 




















Figure 1. Electrospray mass spectrum analysis of immunoaffinity- 
purified connective tissue activating peptide-111 (CTAP-111) isolated 
from human platelets, showing a cluster of +5 charged species 
ranging from m/Z 1,774 to 1,881.5. The mass peaks correspond to 
intact CTAP-111 (A), the noncovalent phosphate adduct of CTAP-111 
(A'), CTAP-111 des 1-3 (B), CTAP-111 des 1-4/beta-thromboglobulin 
(B-TG) (C), and an unidentified component (D). Electrospray mass 
spectrometry generates protein ions having multiple charges by 
spraying them into a vacuum region at high electric potential. The 
mascharge ratio of the ions is measured, allowing the mass of the 
compounds to be calculated from the mascharge ratio for each 
charge state and the ionic charges themselves. The ion peaks at m/Z 
1,550 and m/Z 1,327.5 represent the +6 and +7 charge states, 
respectively. 
counting vial containing Ecolume cocktail, and radioactivity 
was measured in a scintillation counter. 
RESULTS 
Intact CTAP-I11 is the primary isoform present 
in platelets. Earlier we estimated that CTAP-I11 iso- 
lated from washed platelets was -86% intact CTAP- 
III,4% P-TG, and 10% CTAP-I11 des 1-15/NAP-2 (17). 
Since earlier preparations used platelets that had been 
stored frozen for many years, it was possible that 
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Table 1. Connective tissue activating peptide I11 (CTAP-111) isoforms isolated from 6 different platelet preparations* 
Isoform, % Relative specific 
Preparation Intact activityt 
no. Deamidated des 1 des 1-2 des 1-3 des 1-4 CTAP-111 GAG DNA 
P2011 57 NF 10 27 Trace 64 11.0 780 
P2012 53 NF 10 28 NF 63 68.7 956 
P2017 70 14 15 22 Trace 50 99.2 1,049 
P2027 29 NF 5 14 Trace 81 6.1 258 
P2028 25 NF 6 14 Trace 81 41.7 1,881 
P2030 34 NF 7 Trace Trace 93 37.7 1,324 
~~~~~~~ ~~ ~~ ~ ~~ ~~ ~ 
* Quantitation of the various forms of CTAP-111 is based on the quantities of the respective PTH-amino acids in the second sequenator cycle. 
The first cycle was not used for quantitation, to avoid interference from any contaminating free amino acids which might have been present. 
Specific activity was not correlated with age of preparation or the percentage of deamidated or proteolytic isoforms. The percent deamidated 
CTAP-111 is based on the quantities of PTH-Asp and PTH-Asn observed in the first sequenator cycle. The presence of the des 1 form was 
indicated by a high level of PTH-Leu in the first sequenator cycle and PTH-Ala in the second. NF = not found; “trace” indicates <1%. 
t Defined as increase in cpmlpgiml of CTAP-111 in the culture well, determined during the initial portion of the dose-response curve. GAG = 
glycosaminoglycan. 
isoforms formed during prolonged cold storage. In the 
present study we isolated CTAP-I11 from recent plate- 
let packs and used microsequencing and mass spec- 
trometry to determine the CTAP-I11 isoform content. 
CTAP-111 isolated from frozen human platelets ranged 
from 195 to 455 pg/gm of wet platelets (mean -+ SD 333 
? 98 pg/gm). Current CTAP-111 preparations showed 
only a trace of CTAP-111 des 1-15lNAP-2-sized isoform 
with silver stains or Western blots, suggesting that this 
isoform represents < I% of the applied protein. 
Mass spectrometric analysis of CTAP-TI1 iso- 
lated from platelets revealed mostly intact CTAP-I11 
and traces of several cleavage isoforms ; these included 
P-TG, CTAP-111 des 1-3, and a phosphate adduct of 
CTAP-111 (Figure 1). Neither of the latter 2 isoforms 
has previously been reported. Separation by reverse- 
phase high performance liquid chromatography 
showed a large CTAP-111 peak and several small 
peaks; these were shown by Western blotting to be 
reactive with anti rCTAP-111. Sequence analysis con- 
firmed that intact CTAP-I11 was the dominant species 
and also verified the presence of CTAP-I11 des 1-3; the 
other small peaks were apparently blocked and did 
not sequence. 
To better define the frequency and quantity of 
amino-terminal isoforms, 6 CTAP-111 preparations 
were used for amino-terminal sequencing in amounts 
sufficient to permit measurement of secondary and 
tertiary sequences. The results are shown in Table 1. 
These data revealed the presence of the des 1 and des 
1-2 isoforms and confirmed the presence of the des 1-3 
isoform; very little p-TG was found. The 3 oldest 
preparations (isolated between June 1991 and Febru- 
ary 1992) exhibited the most amino-terminal modifica- 
tion; the 3 most recent preparations (isolated between 
June 1992 and August 1992) contained 81-93% intact 
CTAP-111. Neither the degree of amino-terminal de- 
amidation nor amino-terminal proteolytic cleavage 
had a clear effect on the anabolic activities of these 
preparations. 
Molecular isoforms of CTAP-I11 in plasma. 
CTAP-I11 released from the platelet a-granule into the 
plasma may be enzymatically converted to smaller 
isoforms by proteolytic enzymes, including the tryp- 
tic, chymotryptic, and elastase-like enzymes found in 
the platelets themselves (38,39). To evaluate this we 
examined platelet-pack plasma, which contained 
platelet releasate 5-6 days of age, as well as fresh, 
conventional plasma samples. In platelet-pack plasma 
the large concentration of CTAP-I11 (Table 2) is mate- 
rial present at the time of blood donation in addition to 
any contributed by platelets releasing a-granule com- 
ponents on activation by ex vivo storage and/or pre- 
parative procedures. 
Table 2. Plasma concentrations of connective tissue activating 
peptide-111 (CTAP-HI)* 
Source 
(no. of samples) 
CTAP-111, 
ng/ml 
Peripheral veins, healthy adults (26) 54.0 2 10.7 
Peripheral veins, diabetes patients (26) 55.4 ? 19 
60.8 +- 18 Inferior vena cava and coronary sinus (4) 
Aorta and coronary arteries (10) 88.4 f 30.1 
Plasma from platelet packs (8) 51,374 2 15,910 
* Measurements in the first 4 plasma groups were carried out by 
enzyme-linked immunosorbent assay; CTAP-I11 levels in platelet- 
pack plasma were measured by radial immunodiffusion. Values are 
the mean f 1 SD. 
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In earlier studies, CTAP-I11 isolated from plate- 
let-pack plasma showed only the amino-terminal se- 
quence of CTAP-111; no P T G  was detected (24). One 
could argue, however, that selective extraction had 
occurred with salt fractionation; therefore, we reex- 
amined the CTAP-I11 isoform content of platelet-pack 
plasma by extracting it with acid-ethanol (the standard 
extraction method in this study) and then isolating 
CTAP-111 by sequential cation-exchange and immuno- 
affinity chromatography. Fourteen micrograms of this 
material was submitted to 4 cycles of amino-terminal 
sequencing: the sequence detected was N/D-L-A-K-, 
characteristic of CTAP-111; no secondary sequence 
was seen, again indicating that neither F T G  nor 
CTAP-I11 des 1-WNAP-2 was present in significant 
amounts in plasma. We previously reported the fre- 
quent partial deamidation of the NH,-terminal aspar- 
agine of CTAP-I11 isolated directly from platelets (18). 
This modification has no effect on anabolic biologic 
activities. Although not detected by sequencing, it was 
clear that trace amounts of small CTAP-I11 isoforms 
are present in such plasma, as shown by Western blot 
(Figure 2, lane 3). 
The electrophoretic mobility of CTAP-I11 iso- 
forms in plasma samples of 4 healthy volunteers (3 
men, 1 woman) is shown in Figure 3. All contained a 
large CTAP-I11 isoform compatible with the intact 
form. Not even trace amounts of the small isoforms 
were detected. 
Molecular isoforms of CTAP-111 at sites of plate- 
let sequestration. Since certain organs, such as liver 
and spleen, have been considered to be sites of pool- 
ing, sequestration, andlor destruction of platelets, we 
studied CTAP-I11 isoforms detectable in spleen, liver, 
lung, and kidney. Two normal human spleens were 
extracted with acid-ethanol; these preparations con- 
tained 25-35 pg of CTAP-111 isoforms/gm wet weight 
of tissue, as measured by RID. This concentration is 
consistent with what would be expected if 10% of the 
total platelet population (a normal value) were pooled 
in the spleen. One normal spleen preparation was 
further processed by cation-exchange and immuno- 
affinity chromatography; 70 pg of CTAP-I11 isoforms 
was recovered, Amino-terminal sequencing confirmed 
the presence of the intact form of CTAP-111. A West- 
ern blot showed molecular weight species like those 
found in platelet-pack plasma (Figure 2, lane 4). Acid- 
ethanol extracts of liver (Figure 2, lane 5 )  and lung 
(Figure 2, lane 6) contained trace (nanogram) amounts 
of CTAP-I11 isoforms; Western blots (Figure 2) 







CTAP-Ill des 1-1 5/NAP-2 
CTAP-III 
Figure 2. Western blot comparing immunoaffinity-isolated connec- 
tive tissue activating peptide-111 (CTAP-111) and CTAP-I11 des 
1- 15heutrophil activating peptide-2 (NAP-2) with material isolated 
from platelet-pack plasma (lane 3), normal human spleen (lane 4), 
normal human liver (lane 5 ) ,  normal human lung (lane 6), and a 
24-hour collection of human urine (lane 7). See text for details. 
form in association with unique large forms which, 
based on size, may be disulfide-linked multimers. 
CTAP-I11 isoforms in urine and kidney tissue. 
Only nanogram amounts of CTAP-111 isoforms were 
detected in a 24-hour urine sample by Western blot; 
the isoform in urine appeared to be larger than the 
parental form of CTAP-I11 (Figure 2, lane 7). Since the 
mobility of this isoform was not affected by dilution, it 
is doubtful that the apparent larger size was an elec- 
trophoretic artifact related to total protein in the lane. 
The apparent molecular size of the urinary antigen 
may be related to dimerization of an NAP-2-sized 
isoform or a disulfide interchange linking NAP-2- or 
CTAP-111-sized isoforms and unrelated proteins. Kid- 
ney tissue from 2 individuals with normal serum 
creatinine levels was shown to contain microgram 
amounts of CTAP-111. Cortical and medullary compo- 
nents were extracted with acid-ethanol for CTAP-111 
isoforms. In 1 patient, the renal cortex contained 2.3 
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pg of CTAP-III/gm of tissue and the medullary frac- 
tion had 1.8 pg of CTAP-III/gm of tissue; the second 
patient had a larger concentration in the renal medulla 
than in the cortex. Western blot indicated that much of 
the antigen was compatible with intact CTAP-I11 and a 
lesser amount was the size of CTAP-I11 des 1-151 
NAP-2 (Figure 4). Nothing resembling the size found 
in urine was seen. 
Plasma concentrations of CTAP-I11 antigens in 
control and patient groups. Plasma CTAP-I11 concen- 
trations are shown in Table 2. Peripheral venous 
plasma concentrations of CTAP-I11 were similar in the 
healthy controls and in the group of young patients 
with uncomplicated type I diabetes. Since the mean 
age in these 2 groups was 28 years and 24 years, 
respectively, it is reasonable to question whether data 
from older persons would be substantially different. 
The results seen in Figure 5 show that the majority of 
the patients with RA (mean age 50.7 years) had CTAP- 
I11 values within the range found for the younger 
groups. Venous plasma concentrations of CTAP-I11 
from central locations, such as the inferior vena cava 
and coronary sinus, were not significantly different 
from peripheral venous values. 
Mean arterial plasma concentrations of CTAP- 
I11 (Table 2) were somewhat greater than venous 
values (P < 0.001). Arterial blood samples were ob- 
tained from 10 patients just prior to balloon angio- 
plasty ; CTAP-I11 concentrations ranged from 43 ng/ml 
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Figure 3. Western blot comparing 50 ng of authentic platelet- 
derived connective tissue activating peptide-111 (CTAP-111) with 
immunostained substances extracted from the plasma of 4 normal 
subjects. The first lane shows the electrophoretic mobility of puri- 
fied CTAP-I11 applied in a physiologic buffer; the second shows the 
slight retardation in mobility when the peptide is in the more 
protein-rich environment found in acid-ethanol extracts (A). The 4 
plasma samples had the mobility of CTAP-111. Lanes A, B, C, and 
D contain samples from a 66-year-old man, a 41-year-old man, a 
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Figure 4. Western blot comparing immunoaffinity-isolated connec- 
tive tissue activating peptide-I11 (CTAP-111) and neutrophil activat- 
ing peptide-2 (NAP-2) with CTAP-111 antigen extracted from kidney 
tissue from 2 subjects with normal creatinine levels. CTAP-111 and 
NAP-2 sized isoforms were found in both the renal cortex (lane 3) 
and the renal medulla (lane 4). 
within the normal range for peripheral veins. It is not 
clear whether the higher arterial measurements in the 
remaining 6 patients reflect intrinsic abnormalities of 
the arterial intima that induce local platelet activation 
detected by the catheter, or whether trauma inflicted 
by the sampling catheter induced local platelet release 
Figure 5 comuares ulasma CTAP-I11 values in 
RA, SSc, and SLE patients with values in controls. 
The 42 patients with RA included 36 women and 6 
men. Ten of the 42 (24%) had plasma CTAP-I11 values 
that exceeded the normal range. Two patients whose 
disease activity status was judged to be 0 had normal 
plasma CTAP-I11 values. CTAP-111 values were ele- 
vated in 50% of the patients with an activity status of 
1, in 30% of patients with an activity status of 2, and in 
1 of 2 with an activity status of 3. Not only was there 
no consistent relationship between global estimates of 
disease activity and elevated CTAP-I11 values, but 
individuals with clearly active disease frequently had 
normal CTAP-I11 levels. 
Four of 11 patients with progressive systemic 
sclerosis (SSc) had abnormal CTAP-111 plasma values. 
Two samples had markedly elevated levels. Both 
patients were judged to have a disease activity status 
of 3; 1 patient was receiving prednisone, the other 
Of CTAP-111. 
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Figure 5. Peripheral venous plasma values for CTAP-IIIIPTGINAP-2 isoforms, as measured 
by enzyme-linked immunosorbent assay, in normal subjects (N), patients with various 
inflammatory rheumatic diseases (rheumatoid arthritis [RA], systemic sclerosis [SSc], and 
systemic lupus erythematosus [SLE]), and dialysis-dependent patients with chronic renal 
disease. In the latter group, 5 were treated with hemodialysis (circles) and 5 with peritoneal 
dialysis (triangles). See Figures 1 and 2 for other definitions. 
penicillamine. The 2 SSc patients with slightly ele- 
vated plasma CTAP-I11 values had less active disease 
(activity status of 1 and 2). Among the 7 SSc patients 
with normal plasma CTAP-I11 values, all were judged 
to have an activity status of 1 or 2. 
Three of 20 patients with SLE had abnormal 
plasma CTAP-I11 values; all 3 had disease activity 
status scores of 3.  One had proteinuria, and 1 had 
mesangial proliferation, but none had renal failure. Of 
the 17 SLE patients with normal plasma CTAP-I11 
measurements, only 2 were judged to have inactive 
disease; the remaining 15 had variable activity values, 
ranging from scores of 1 in 4 patients to scores of 3 in 
6 patients. 
Molecular isoforms of CTAP-I11 in patients with 
RA. Western blotting of plasma extracts from 4 
women with active RA and elevated plasma CTAP-I11 
values showed only a large molecular isoform of 
CTAP-I11 (results not shown). This contrasts with the 
finding of small isoforms in the synovial tissue itself in 
this disease (28). 
Plasma CTAP-I11 antigen concentrations in pa- 
tients with severe renal disease. Strikingly elevated 
concentrations of plasma CTAP-I11 antigens were 
found in patients with chronic renal failure (Figure 5) ;  
the values in the figure reflect CTAP-I11 concentra- 
tions measured just prior to hemodialysis or at random 
times during ongoing peritoneal dialysis. After 30 
minutes of hemodialysis, values decreased in 3 pa- 
tients, and increased in 2. Values at the conclusion of 
dialysis were increased over initial values in 3 patients 
(47%, 71%, and 140%), unchanged in 1 ,  and decreased 
in 1 (33%). Hemodialysis patients had lower plasma 
levels of CTAP-111, on average, than did the peritoneal 
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dialysis patients (mean k SD 530 k 399 ng/ml versus 
1,090 2 386 ng/ml). The lower levels of CTAP-I11 in 
the hemodialysis patients are probably not attributable 
to clearance of CTAP-I11 by the hemodialysis mem- 
branes, since the levels of CTAP-111 did not consis- 
tently fall during the 3-4 hours of hemodialysis. 
Three of the 4 patients with the highest CTAP- 
111 values (1  receiving hemodialysis and 3 receiving 
peritoneal dialysis) had recently had infection requir- 
ing parenteral antibiotics; however, no other underly- 
ing renal or systemic diagnoses were associated with 
consistently high CTAP-111 values. Furthermore, pa- 
tients with high CTAP-I11 levels had no consistent 
differences in recent laboratory values (e.g., levels of 
blood urea nitrogen, serum creatinine, electrolytes, or 
calcium, or findings on liver function tests), hemato- 
logic indicators (e.g., white blood cell count, platelet 
count, hemoglobin level), or use of specific medica- 
tions (e.g., erythropoietin, vitamin D analogs, anti- 
hypertensive agents, or antibiotics). Peritoneal dialy- 
sis fluid was studied for CTAP-I11 content by ELISA 
after 3 hours of equilibration in the peritoneal cavity; 
the mean k 1 SD level in the 5 samples was 47 k 2.9 
ng/ml, averaging 5.0 k 1.9% of the concurrent plasma 
values. This is consistent with equilibration data de- 
termined for other substances of similar molecular 
size, such as beta-2-microglobulin (40). 
CTAP-I11 isoforms in patients with severe renal 
disease. Western blots of extracted plasma samples 
from dialysis patients showed a large CTAP-I11 iso- 
form compatible with the 85-residue parental protein 
(Figure 6). A sample of peritoneal dialysis fluid from 1 
of these patients was lyophilized and processed in a 
manner similar to plasma. Western blot showed only the 
large CTAP-111 isoform (results not shown). There was 
no evidence of a proteolytic cleavage isoform conse- 
quent to transport across the peritoneal membrane. 
Sensitivity of peritoneal cells to CTAP-I11 in 
vitro. Since we were able to propagate fibroblast-like 
cells released into the peritoneal dialysis fluid, it was 
possible to test whether cells derived from the perito- 
neum were metabolically responsive to CTAP-111 at 
the concentrations (1-2 pg/ml) shown to be present at 
the capillary-peritoneal interface. A comparison of the 
stimulatory effect of CTAP-I11 on peritoneal and syno- 
vial cells in monolayer culture is shown in Figure 7. 
CTAP-111, 1-2 pg/ml, stimulated I4C-GAG synthesis 
by 50-100% ( P  < 0.001) in peritoneal fibroblast cul- 
tures. As seen in Figure 7, this level of responsiveness 
was similar to that of human synovial cells; however, 
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Figure 6. Western blot showing the mobility of the CTAP-I11 iso- 
forms found in the plasma of patients with renal disease receiving 
long-term peritoneal dialysis (lanes 6-10). Lanes 4 and 5 show that 
the CTAP-I11 isoform from patient 1 (lane 6) comigrates with 
CTAP-111 but not with NAP-2. No small CTAP-111 isoforms were 
seen in the plasma from these 5 patients; the increased band 
density reflects the higher plasma levels of CTAP-111 antigen found 
by enzyme-linked immunosorbent assay. Western blots of plasma 
from 5 patients treated with hernodialysis yielded results similar to 
those seen here. 
higher concentrations of CTAP-111. Basal synthesis of 
3H-DNA in peritoneal fibroblasts was much lower than 
that in synovial cells; nevertheless, the peritoneal cells 
were stimulated to synthesize 5040% more 3H-DNA 
by the lower concentrations of CTAP-I11 ( P  < 0.005). 
Arterial plasma CTAP-I11 antigens at angio- 
plasty sites. The mean 2 SD degree of coronary artery 
stenosis prior to angioplasty was 66 k lo%, as judged 
by caliper measurement. Post-angioplasty measure- 
ment showed that the stenosis had been reduced to 40 
k 9%. Intracoronary plasma CTAP-I11 antigen mea- 
surements before and after angioplasty are shown in 
Table 3. The data suggest that intracoronary CTAP-111 
may rise early after angioplasty, with a peak seen within 
the first few minutes, concordant with the timing of 
platelet deposition noted in other studies (41). 
DISCUSSION 
The pathophysiologic significance of increased 
amounts of CTAP-I11 in plasma and tissues derives 
from the known proinflammatory activities of CTAP- 
111 isoforms. The CTAP-I11 des 1-15/NAP-2 isoform is 
a potent stimulator of neutrophil activation and che- 
motaxis, and the isoforms that have been most studied 
(CTAP-I11 the des 1-13, des 1-14, and des 1-IYNAP-2) 
activate connective tissue cells to stimulate mitogene- 
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Figure 7. Comparison of the stimulatory effects of connective tis- 
sue activating peptide-I11 (CTAP-111) in synovial and peritoneal 
connective tissue cells in monolayer culture. Synovial and perito- 
neal cells both responded to the anabolic effects of CTAP-I11 at 
concentrations of 1-2 pg/ml, levels similar to those found in the 
plasma of patients with end-stage renal disease. 14C-GAG = 14C- 
glycosaminoglycan. 
sis and extracellular matrix synthesis. It is possible 
that the heparin-binding capability of these isoforms 
may serve to concentrate them in inflammatory tissue 
and amplify focal biologic activity. 
The relative abundance of CTAP-111 provides a 
unique opportunity to study the distribution, the in 
vivo processing, and possibly the ultimate fate of a 
potent cytokine. The total circulating platelet popula- 
tion of -1.42 x lo'* platelets contains -130 mg of 
CTAP-111; if one postulates a platelet survival time of 
10 days, then -13 mg is released from platelets each 
day. The total CTAP-I11 found in the plasma amounts 
to only 120 pg, while that detected in the urine is only 
'100 ng per day. Measurements of CTAP-111 in joint 
fluid, which may be considered a specialized intersti- 
tial space, are similar to levels in concurrently ob- 
tained plasma (42). If the plasma half-time for the 
CTAP-IWp-TG antigen is 100 minutes (4), the steady- 
state concentration of the CTAP-111 antigen in extra- 
cellular water (plasma plus interstitial fluid) can be 
estimated to be 101 nglml. This value exceeds the 
measured mean value in normal individuals (54 * 10.7 
ng/ml [ +SD]), possibly indicating that the actual half- 
time operative under physiologic conditions is some- 
what shorter (-50 minutes) and/or that a substantial 
proportion of the CTAP-111 released daily by spent 
platelets never reaches the plasma due to destruction 
and/or restriction to limited cellular compartments. 
The surprisingly high concentrations of CTAP-111 in 
the kidney may be an example of this latter possibility. 
We have shown, by Western blots, sequence 
analysis, and mass spectrometry, that intact CTAP-I11 
is the dominant isoform in this antigen family; this was 
true in the platelets of origin, in platelet-pack plasma, 
and in the spleen. While there was <1% P-TG, we 
found larger amounts of amino-terminal deamidated 
CTAP-111, as reported earlier (18), as well as CTAP-I11 
des 1, des 1-2, and des 1-3, all isoforms not previously 
recognized. These data contradict the earlier belief 
that p-TGICTAP-I11 des 1-4 was the naturally occur- 
ring entity in platelets and plasma. The proportion of 
smaller isoforms (such as NAP-2) found in platelets, 
plasma, and spleen was small (<1%) and detected only 
on Western blots; this contrasts with data from RA 
and OA synovial tissue extracts, where small isoforms 
accounted for 30-100% of the antigen (24). 
Elevated plasma CTAP-I11 values in patients 
with RA, SLE, and SSc were found with approxi- 
mately the same frequency as in earlier studies (15,16). 
Abnormal values were not present in all patients with 
active disease; however, all elevated values occurred 
in patients with clinical evidence of disease activity. 
Increased plasma levels of CTAP-I11 may result from 
episodic release due to intravascular platelet activa- 
tion induced by multiple substances (such as DNA, 
IgG, or complement components), and in the peri- 
phery, at sites of recent microvascular lesions. The 
Table 3. Intracoronary connective tissue activating peptide 111 
(CTAP-111) values after percutaneous transluminal coronary angio- 
plasty (PTCA)* 
Time CTAP-111, ng/ml 
Baseline 68 f 8 
1 minute post-PTCA 
5 minutes post-PTCA 
10 minutes post-PTCA 
15-20 minutes post-PTCA 
94 5 24 
140 f 391 
120 * 26$ 
1 1 1  5 40 
~ 
* Values are the mean ? 1 SD. 
t P = 0.07 versus baseline, by Mann-Whitney U test. 
$ P = 0.09 versus baseline, by Mann-Whitney U test. 
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degree to which medications (such as glucocorticoids 
or nonsteroidal antiinflammatory drugs) modify plate- 
let activation is uncertain. 
While only nanogram amounts of CTAP-I11 
isoforms were detected in normal 24-hour urine sam- 
ples, normal renal cortex and medullary tissue had 
microgram amounts of CTAP-I11 per gram of tissue. 
Much of the antigen was intact CTAP-111, and part was 
the size of CTAP-I11 des 1-15/NAP-2. These values are 
roughly 40-fold the values in normal plasma 500-1,000 
times our estimates for liver, lung, and aorta. If the 
9-kd plasma CTAP-I11 (50 ng/ml) is freely filtered 
through the glomerulus and reabsorbed by the tubules, 
more than half of the CTAP-I11 disposed of each day 
(-8.5 mg) is delivered to the tubules, but only traces 
appear in the urine. Thus, it is not unreasonable to 
anticipate substantial amounts of extractable CTAP- 
I11 in the renal parenchyma; present measurements of 
renal tissue account for 7 4 %  of the postulated filtered 
load of cytokine. Alternative explanations for the 
“missing” portion of the renal CTAP-I11 include the 
possibilities that 1) it may be rapidly destroyed by 
proteolysis following tubular absorption, or 2) less 
likely, the cytokine may not be completely filtered. 
The physiologic significance of renal localiza- 
tion of CTAP-I11 may lie in certain structural charac- 
teristics of the kidney. Our studies of the glycosamin- 
oglycans of canine kidney showed the cortex to be rich 
in heparitin sulfate, with lesser amounts of dermatan 
sulfate; the medulla, on the other hand, contains 
mostly hyaluronic acid (43). Among adult tissues, only 
joint fluid and cartilage have higher concentrations of 
hyaluronate than are found in the renal medulla. One 
might speculate that delivery of an “HA synthesis- 
stimulating cytokine” (such as CTAP-111) is important 
for maintenance of the high medullary concentrations 
of HA; the level of CTAP-I11 that we detected is 
adequate to stimulate GAG (especially HA) synthesis 
by many cell types. In patients with end-stage renal 
disease, where elimination and storage of CTAP-III 
was impaired, plasma CTAP-I11 values rose to levels 
of 300-1,800 ng/ml. CTAP-I11 in such elevated levels 
was shown to be capable of promoting DNA and GAG 
synthesis in vitro in peritoneal fibroblast-like cells. 
Several studies have provided transport data 
showing that patients receiving long-term peritoneal 
dialysis frequently show decreased peritoneal men: - 
brane permeability and histologic evidence of mem- 
brane thickening and collagen deposition (4447). It is 
possible that high levels of CTAP-I11 (and other cyto- 
kines) may be critical to these changes. 
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